Replies to post #116280 on Biotech Values

[flatlander_60048]

What if anything does this say about the likely outcome of the tials comparing Lucentis to Avastin.

I mean it seems like Roche is in a good position to know the positives and negatives of each drug, yet they chose to run expensive trials for the DME indication for Lucentis. Would Roche do this if they suspected that the trial outcome would show that Avastin would compare favorably to Lucentis?

FL